Survival curves showed that higher levels of E2F1 or MYBL2 mRNA were correlated with poor prognosis in patients with GC, as evidenced by shorter overall survival (OS), first-progression survival (FPS), and post-progression survival (PPS) (Fig. 1, G and H). Here, E2F1 is linked to gastric cancer.